Stigmastanol (Sitostanol): A Comprehensive Encyclopedic Reference
1. Identity and Chemical Characterization
Names and Synonyms
Stigmastanol carries the CAS registry number 19466-47-8 and the molecular formula C29H52O with a molecular weight of 416.72 g/mol. Its IUPAC name is (3β)-Stigmastan-3-ol. It is also known by the synonyms β-sitostanol, 24α-ethylcholestanol, stigmastan-3β-ol, fucostanol, spinastanol, and BETA-SITOSTANOL, among others. Stigmastanol is also called β-sitostanol, the saturated form of the plant sterol stigmasterol, and is closely related in structure to campestanol, the saturated counterpart of campesterol.
Chemical Structure
Stigmastanol is a phytostanol — the saturated form of the plant sterol β-sitosterol — that structurally resembles cholesterol but features an ethyl group at the C-24 position and lacks double bonds in its steroid nucleus. Phytosterols are naturally occurring compounds found in plant cell membranes that are structurally similar to cholesterol, only differing in the presence of ethyl or methyl groups and additional double bonds in the side chain. Because stigmastanol is fully saturated, it is classified as a stanol rather than a sterol; sterols retain at least one double bond in their ring system, while stanols do not.
Stigmastanol is a white to off-white crystalline solid at room temperature. Its molecular weight is 416.72 g/mol, and it has a melting point of 144 °C. The compound exhibits very low solubility in water, with a predicted water solubility of approximately 3 × 10−9 mol/L, reflecting its highly non-polar character. In contrast, it is slightly soluble in chloroform and more readily soluble in fats and organic solvents such as ethanol and ether, consistent with its lipophilic nature.
Relationship to Stigmasterol and β-Sitosterol
Stigmastanol is the product of the reduction of β-sitosterol and the hydrogenation of stigmasterol. Stigmasterol is synthesized via the mevalonate biosynthesis pathway and has structural similarity to β-sitosterol but differs in the presence of a trans-oriented double bond in the side chain. When that double bond (and the ring double bond of β-sitosterol) is removed by catalytic hydrogenation, the product is stigmastanol — a fully saturated molecule. This relationship means that stigmastanol is simultaneously the hydrogenation product of two distinct, closely related plant sterols.
Natural Botanical Sources
Stigmastanol, a saturated phytostanol, occurs naturally in various plant materials, serving as a minor component of the phytosterol profile in many species. Primary natural sources include cereal grains such as wheat bran, rye, corn, and barley, where it contributes to the stanol fraction of total phytosterols. Major plant sterols found in barley included sitosterol, stigmasterol, campesterol, brassicasterol, δ5-avenasterol, and δ7-avenasterol; others were stigmastanol and stigmastadienol. Of more than 250 sterols and stanols known to exist in nature, only six — including sitostanol — are dominant in seed oils (rapeseed, soybean, corn, and sunflower oils), other grains (corn, rye, wheat, barley, millets, rice, oats, and peanuts), and tree oils.
The most common plant stanols in the human diet are sitostanol (stigmastanol) and campestanol, which combined make up about 5% of dietary phytosterol. The consumption of phytosterols can range between 170 mg/day in populations eating a Western diet and 360 mg/day in diets rich in vegetable products. The dietary intake of plant stanols is usually only about 50 mg/day unless the diet is supplemented with tall oil, which is derived from conifers and is rich in sitostanol.
Commercial Production and Forms
In natural extraction processes, β-sitosterol isolated from sources like soybean or rapeseed oil deodorizer distillates is subjected to catalytic hydrogenation to saturate the double bonds, yielding stigmastanol. This typically involves palladium on carbon (Pd/C) as the catalyst under hydrogen pressure in a suitable solvent, such as ethyl acetate, at room temperature for several hours, achieving high selectivity for the desired saturated product.
The present commercial source of plant stanol is extraction from a byproduct in the refining of vegetable oils or from the oil obtained from pinewood pulp in papermaking. Plant stanols are much less abundant than sterols in the natural state but can be produced commercially by hydrogenation of sterols. Esters of sterols and stanols are also produced commercially to enhance their solubility in food products.
Plant sterols can be hydrogenated to form plant stanol esters (e.g., sitostanol, campestanol, stigmastanol), a process that improves their solubility in margarine. Currently, phytosterols are available incorporated into various fat-based food products such as spreads, milk, yogurt and low-fat food products such as cereal, bread, and orange juice. In most cases they are esterified to unsaturated fatty acids (sterol esters) to increase lipid solubility, thus allowing maximal incorporation into a limited amount of fat.
2. Traditional and Historical Use
Context: Phytosterols as Dietary Constituents
Stigmastanol as a discrete, isolated compound has no documented pre-modern or traditional medicinal use in any specific cultural tradition. As a minor constituent of the stanol fraction of everyday plant foods — cereal grains, vegetable oils, nuts, seeds, and legumes — it has been consumed throughout human history as part of normal dietary intake, without any historical tradition of deliberate supplementation or therapeutic extraction.
Since the 1950s, plant sterols have been known to effectively reduce serum cholesterol levels. It has been known since the 1950s that plant sterols lower blood cholesterol levels. The deliberate therapeutic use of sitostanol specifically as a cholesterol-lowering agent therefore belongs entirely to the modern scientific era, originating in clinical pharmacology research rather than in traditional ethnobotanical use.
Early Scientific Interest and Pre-Commercial Use (1950s–1990s)
The cholesterol-lowering effect of dietary plant sterols (phytosterols) has been studied since the 1950s. Earlier studies showed that large amounts of sitosterol (≥10 g/d) lowered serum cholesterol levels by 10–20%. The high dosage and the chalky taste of sitosterol limited its use; Grundy and Mok (1976) subsequently demonstrated that 3 g/d of sitosterol was sufficient to lower serum cholesterol levels. They suggested that plant sterols could be considered a form of dietary treatment rather than a drug to lower cholesterol because plant sterols are naturally present in plant-based foods.
The differences in the various plant sterols became apparent when saturated derivatives of plant sterols, called plant stanols, were shown to reduce serum cholesterol at low doses. The first description of the use of plant stanols to lower plasma cholesterol was by Heinemann et al. in 1986. The investigators showed that administration of capsules of sitostanol dispersed in sunflower oil at a dose of 1.5 g/day lowered LDL cholesterol by 15% in hypercholesterolemic adults; plasma sitostanol levels were undetectable during the study in most individuals.
This process was patented by the Finnish company Raisio Group in 1989 and resulted 6 years later in their marketing Benecol margarine. During the interim, a number of studies were conducted by Miettinen et al. at the University of Helsinki. The problem of poor lipid solubility was overcome by esterifying plant stanols with fatty acids, with the resultant stanol esters being freely soluble in fat spreads. This led to the launch of Benecol (margarine; Raisio Group, Raisio, Finland) in 1995. The coincident publication of the year-long North Karelia study conclusively demonstrated the long-term LDL-lowering efficacy of plant stanol esters.
3. Key Constituents and Mechanisms of Action
Active Compound
The biologically active entity is stigmastanol (sitostanol) itself, typically administered as its fatty acid ester (e.g., the rapeseed oil fatty acid ester in Benecol). Both classes of compound — plant sterols and stanols — competitively inhibit the absorption of cholesterol and thus lower its level in plasma.
Primary Mechanism: Inhibition of Intestinal Cholesterol Absorption
Plant sterols appear to decrease the solubility of cholesterol in the oil and micellar phases, thus displacing cholesterol from bile salt micelles and interfering with its absorption. Humans cannot synthesize plant sterols and they are poorly absorbed. When consumed they replace cholesterol in intestinal micelles, thereby interfering with cholesterol absorption.
Plant stanols are virtually unabsorbable, which makes them more ideal hypocholesterolemic agents than plant sterols. According to Heinemann and coworkers, sitostanol inhibited in an infusion experiment the absorption of cholesterol by 82%, whereas sitosterol respectively inhibited the absorption by 50%. The greater efficacy of the stanol form compared to the corresponding sterol is thus well-documented in controlled experimental conditions.
Crystalline plant sterols do not to a significant degree dissolve in the micellar phase in the alimentary canal, and are therefore not capable of efficiently inhibiting cholesterol absorption. Oils and fats are only to a limited degree capable of dissolving free sterols. Only in a dissolved form do sterols inhibit the absorption of cholesterol. This explains why esterified preparations consistently outperform crystalline free-stanol capsules in clinical settings.
Secondary Mechanism: Hepatic Cholesterol Synthesis
Similar to sterol esters and stanol esters, stigmastanol inhibits the absorption of cholesterol from the diet. Animal studies suggest that it also inhibits biosynthesis of cholesterol in the liver. Consumption of a sitostanol-containing mixture (1% dietary levels) caused a compensatory increase in cholesterol synthesis as indicated by elevated lathosterol/cholesterol ratios in plasma and hepatic cholesterol fractional synthesis rate. This compensatory upregulation of endogenous cholesterol synthesis is an expected homeostatic response to reduced intestinal absorption.
Minimal Absorption and Systemic Exposure
Plasma phytosterol levels in mammalian tissue are normally very low due primarily to poor absorption from the intestine and faster excretion from the liver compared to cholesterol. The structural differences of plant stanols and sterols from cholesterol render them minimally absorbable in the intestine — in the range of 0.5–2% for plant sterols. As a result of low absorption and efficient excretion after uptake by the liver, circulating levels are low, varying from 0.3–1.0 mg/dL for plant sterols.
Despite increased serum sitostanol contents during plant stanol ester consumption, arterial levels were unchanged, suggesting that sitostanol is not taken up into the arterial wall.
4. Scientific Evidence by Area of Use
4.1 Cardiovascular Health: LDL Cholesterol Reduction
Overview of Evidence
Consumption of plant sterols has been reported to reduce low-density lipoprotein (LDL) cholesterol concentrations by 5–15%. The evidence base for stigmastanol/sitostanol specifically is among the most extensively studied in the plant stanol/sterol category, supported by multiple randomized controlled trials, meta-analyses, and regulatory body assessments.
Landmark Clinical Trial: The North Karelia Study (1995)
Soluble sitostanol was tested for tolerability and cholesterol-lowering effect in margarine containing sitostanol ester in a population with mild hypercholesterolemia. A one-year, randomized, double-blind study was conducted in 153 randomly selected subjects with mild hypercholesterolemia. Fifty-one consumed margarine without sitostanol ester (the control group), and 102 consumed margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day). The margarine containing sitostanol ester was well tolerated. The mean one-year reduction in serum cholesterol was 10.2 percent in the sitostanol group, as compared with an increase of 0.1 percent in the control group. Specifically, results from this study show that a daily intake of 1.8–2.6 g of fat-soluble sitostanol ester (calculated as free stanol) administered in a margarine decreased total cholesterol by 10% and LDL-cholesterol by 14% compared to the reference group.
Ester Form vs. Free Stanol
Feeding of margarines containing sitostanol (CAS 19466-47-8), sitostanol acetate (CAS 73052-08-1), sitostanol oleate (CAS 107615-79-2), or placebo (equivalent of 0.5 g of sitostanol t.i.d.) on cholesterol absorption and serum lipids were studied in 10 normolipemic volunteers in a randomized double-blind cross-over trial. The study was divided into an open one-week run-in phase and four one-week treatment periods. Cholesterol absorption during placebo, sitostanol, sitostanol acetate, and sitostanol oleate feeding averaged 41.6%, 10.2%, 17.0%, and 20.5%, respectively (p < 0.001 for all against placebo). LDL cholesterol was proportionally reduced by 22% (p < 0.001), 14% (p < 0.05), and 8% (ns) for the respective ester forms. The results indicate that unesterified sitostanol is more effective in inhibiting cholesterol absorption and reducing LDL cholesterol than the acetate or oleate esters.
Negative Evidence: Capsule Form and Low-Cholesterol Background Diet
Plant sterols have been shown to reduce dietary cholesterol absorption and hence, total and LDL-cholesterol concentrations in humans. In one study, the cholesterol-lowering effects of dietary supplementation with the hydrogenated plant sterol sitostanol (3 g/d) were tested in 33 men with moderate hypercholesterolemia who were consuming an outpatient diet in which dietary cholesterol was restricted to <200 mg/d. Sitostanol therapy did not significantly lower LDL cholesterol compared with the diet alone. Similarly, sitostanol therapy in conjunction with a cholesterol-lowering regimen of diet and 8 g cholestyramine did not significantly lower LDL-cholesterol concentrations. In a separate assessment, the total daily intake of sitostanol was 3000 mg provided in 12 capsules. The sitostanol capsule regimen did not significantly reduce LDL cholesterol levels compared to the diet alone. Due to the low solubility of free sitostanol in vegetable oils, the use of capsules containing free sitostanol suspended in safflower oil does not ensure that the sitostanol is efficiently distributed into the fat phase of the food digest.
These findings highlight that the physical form and food matrix in which sitostanol is delivered are critical determinants of its efficacy — a consistent theme in the research literature.
Efficacy in Familial Hypercholesterolemia and Statin Co-therapy
Each individual in one study replaced part of his or her daily dietary fat with 25 g of 80% rapeseed oil margarine containing stanol esters (2.24 g/d stanols, mainly sitostanol). The families who consumed this margarine for 12 weeks included 24 children aged 3 to 13 years with the North Karelia variant of FH (FH-NK), 4 FH-NK parents, and 16 healthy family members, and a separate group of 12 FH-NK adults who consumed the margarine for 6 weeks and who were on simvastatin therapy (20 or 40 mg/d). Sitostanol has an additive effect with the statins in lowering LDL cholesterol.
Regulatory-Level Assessment: EFSA and FDA
The European Food Safety Authority (EFSA) concluded that blood cholesterol can be reduced on average by 7 to 10.5% if a person consumes 1.5 to 2.4 grams of plant sterols and stanols per day, an effect usually established within 2–3 weeks. Longer-term studies extending up to 85 weeks showed that the cholesterol-lowering effect could be sustained. Based on this and other efficacy data, the EFSA scientific panel provided the following health advisory: "Plant sterols have been shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of coronary heart disease."
The FDA has approved the following claim for plant sterol esters: foods containing at least 0.65 g per serving of plant sterol esters, eaten twice a day with meals for a daily total intake of at least 1.3 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease. For plant stanol esters: foods containing at least 1.7 g per serving of plant stanol esters, eaten twice a day with meals for a total daily intake of at least 3.4 g, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease.
In 2000, the FDA issued an interim final rule allowing a health claim for reducing the risk of CHD for foods that contain phytosterols and are low in saturated fat and cholesterol. Since 2001, NCEP ATP III has recommended a daily intake of 2 g of phytosterol/stanol esters as a therapeutic option to enhance LDL-C lowering.
Evidence Strength Assessment
The evidence that stigmastanol/sitostanol (in its esterified form incorporated into a fat-containing food matrix) reduces LDL cholesterol is rated as strong, based on multiple randomized controlled trials, meta-analyses, and formal conclusions by EFSA and the FDA. Effect sizes of approximately 10–15% LDL reduction at doses of 1.8–2.6 g/day (as sitostanol equivalent) are well replicated. Evidence for the free crystalline form administered in capsules on a low-cholesterol background diet is weak to absent, as demonstrated by at least one adequately powered clinical trial.
4.2 HDL Cholesterol and Triglycerides
Although a relatively wide range of responses has been reported, most work suggests an expected LDL-C lowering of 5%–10% in individuals with high cholesterol. The effects of sitostanol on HDL cholesterol and triglycerides are generally considered neutral in the clinical literature, with the primary benefit being selective LDL reduction. The research literature as a whole does not support a significant effect of plant stanol esters on either HDL or triglyceride concentrations.
4.3 Additive Effect with Statin Therapy
As co-therapy with statin drugs, phytosterols provide additional LDL cholesterol lowering that is more effective than doubling the statin dose. Given that the mechanism is at the point of absorption, this response can be additive to other LDL-C lowering approaches, such as statin therapy. This additive effect is mechanistically sound: statins reduce endogenous synthesis while stanols reduce intestinal absorption, acting on complementary pathways.
4.4 Phytosterolemia (Sitosterolemia): Therapeutic Role
Sitosterolemia or phytosterolemia is a rare genetic disorder that causes a massive buildup of plant sterols in the body and blood. It affects fewer than one in 1 million people, although it might be underdiagnosed. Research has evaluated the effect of sitostanol specifically in managing phytosterolemia by competitively reducing sterol absorption. This remains a specialized area with limited but mechanistically supported evidence.
5. Body Systems and Health Areas of Association
- Cardiovascular system: Phytosterols have been studied for their beneficial effects in preventing CVD, mainly through inhibiting the absorption of cholesterol. Stigmastanol is specifically associated with LDL-cholesterol reduction and, by extension, cardiovascular disease risk reduction.
- Gastrointestinal system / intestinal absorption: The primary site of action is the small intestine, where stigmastanol competes with dietary and biliary cholesterol for incorporation into mixed micelles, thereby reducing cholesterol absorption.
- Hepatic metabolism: Animal studies suggest that stigmastanol also inhibits biosynthesis of cholesterol in the liver. Whether this secondary hepatic effect is clinically significant in humans requires further investigation.
- Lipid metabolism / plasma lipoproteins: The compound directly impacts LDL particles, the primary carriers of circulating cholesterol, since lowering blood LDL-cholesterol concentrations is a beneficial physiological effect and elevated blood LDL-cholesterol concentration is a risk factor for coronary heart disease.
6. Dosage Forms and Dosages Reported in Studies
Phytosterols are available incorporated into various fat-based food products such as spreads, milk, yogurt, and low-fat food products such as cereal, bread, and orange juice. In most cases they are esterified to unsaturated fatty acids (sterol esters) to increase lipid solubility, thus allowing maximal incorporation into a limited amount of fat.
- Sitostanol ester in margarine, 1.8–2.6 g/day (as free stanol equivalent): A one-year, randomized, double-blind study in 153 subjects used 1.8 or 2.6 g of sitostanol per day delivered in a margarine.
- Sitostanol ester in margarine, 2.24 g/day (mainly sitostanol): Each individual in one study replaced part of his or her daily dietary fat with 25 g of 80% rapeseed oil margarine containing stanol esters (2.24 g/d stanols, mainly sitostanol).
- Free sitostanol in capsules, 1.5 g/day: The first description of the use of plant stanols to lower plasma cholesterol showed that administration of capsules of sitostanol dispersed in sunflower oil at a dose of 1.5 g/day lowered LDL cholesterol by 15% in hypercholesterolemic adults.
- Free sitostanol in capsules, 3 g/day (ineffective in one study): The total daily intake of sitostanol was 3000 mg provided in 12 capsules. The sitostanol capsule regimen did not significantly reduce LDL cholesterol levels compared to the diet alone.
- Free sitostanol in margarine, 0.5 g three times daily: Feeding of margarines containing sitostanol equivalent to 0.5 g of sitostanol t.i.d. (i.e., 1.5 g/day total) on cholesterol absorption and serum lipids were studied in 10 normolipemic volunteers.
- EFSA-identified effective range: The EFSA concluded that blood cholesterol can be reduced on average by 7 to 10.5% if a person consumes 1.5 to 2.4 grams of plant sterols and stanols per day.
- NCEP/FDA recommended intake for therapeutic effect: Maximal LDL-C lowering attributable to plant sterols occurs at a dose of about 2 g/d. Plant stanol esters at a level of 2–3 g/d have been shown to reduce LDL cholesterol by 10–15% without side effects.
A critical determinant of efficacy across all reported dosages is the physical delivery matrix. Initial impressions were that stanols were more effective and safer than sterols, but the negative outcome of a study led to the recognition that the lipid solubility of free stanols was very limited. This was overcome by esterifying them with fatty acids, with the resultant stanol esters being freely soluble in fat spreads.
7. Safety Considerations and Interactions
General Tolerability
The margarine containing sitostanol ester was well tolerated in the landmark one-year North Karelia study. Plant sterols have been considered as a safe way of lowering serum cholesterol levels, since they are natural components of vegetable fats and oils. Long-term experience with plant stanol ester (up to 52 weeks) in clinical studies is augmented by up to 5 years of population-based experience in Finland and 1 year in the U.S. Substantially more data are available on the efficacy, safety, and long-term consumption of plant stanol ester compared to newer plant sterol-enriched formulations.
Effect on Fat-Soluble Vitamins and Carotenoids
The primary concern regarding phytosterol supplementation is the effect it may have on the absorption and circulating levels of lipid-soluble vitamins and carotenoids. Dietary phytosterols inhibit the absorption of dietary and biliary cholesterol, which in turn decreases the absorption of carotenoids and lipid-soluble vitamins. Effects on some lipid-soluble vitamins and carotenoids may be offset by an adequate dietary intake. An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations.
No significant changes were found in serum fat-soluble vitamin and carotenoid concentrations when related to serum total cholesterol in one comparative trial of stanol ester margarines.
Phytosterolemia / Sitosterolemia
Plant sterols are dangerous for people with sitosterolemia. In sitosterolemia, a person will absorb plant sterols in extreme excess because their body cannot tell apart cholesterol from plant sterols. Sitosterolemia is associated with fatty growths underneath the skin, heart complications, and the breakdown of red blood cells.
EFSA Regulatory Status and Novel Food Authorization
The EFSA Panel on Nutrition, Novel Foods and Food Allergens was asked to provide an opinion on the safety of a change of the specifications of the authorised novel food 'phytosterols/phytostanols'. This authorised novel food concerns phytosterols extracted from plants and which may be presented as free sterols and stanols or esterified with food-grade fatty acids. In 2017, existing authorizations for free and esterified phytosterols and stanols extracted from plants were transferred into the EU Union list for novel foods and are now covered by the entry 'phytosterols/phytostanols'.
Current science shows that the lowest effective daily intake of free phytosterols is 800 mg/day with the minimum addition of 400 mg free phytosterols per serving, and that the phytosterol substance should consist of at least 80% sitosterol, campesterol, stigmasterol, sitostanol, and campestanol (combined weight).
Stanol Serum Levels During Supplementation
Both sitostanol and sitostanol-free mixtures at 0.5% or 1% dietary intake levels increased plasma campesterol and beta-sitosterol levels, while plasma sitostanol levels were negligible. This near-zero systemic absorption of sitostanol itself during supplementation is considered a key safety advantage, as it limits systemic exposure to the molecule.
Drug Interactions
No direct pharmacokinetic drug–drug interactions between stigmastanol and prescription medications have been established in the peer-reviewed literature reviewed here. The established co-administration pattern is with statins, which is considered beneficial (additive LDL-lowering). However, as co-therapy with statin drugs, phytosterols provide additional LDL cholesterol lowering that is more effective than doubling the statin dose — a clinically significant interaction with therapeutic implications rather than a safety concern.
References
Go back